Company profile for IO Biotech

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

IO Biotech is a clinical stage biotech company developing disruptive immune modulating anti-cancer therapies. We are focused on the development of immunological treatment of cancer with a research profile based on successful R&D discoveries, translated into numerous clinical trials. IO Biotech has achieved a proven track record of progressing pre-clinical and clinical compounds: Two lead anti-cancer therapies targeting I...
IO Biotech is a clinical stage biotech company developing disruptive immune modulating anti-cancer therapies. We are focused on the development of immunological treatment of cancer with a research profile based on successful R&D discoveries, translated into numerous clinical trials. IO Biotech has achieved a proven track record of progressing pre-clinical and clinical compounds: Two lead anti-cancer therapies targeting IDO and PD-L1 are in clinical development Several compounds finalizing the preclinical phase

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Denmark
Address
Address
IO Biotech ApS Ole Maaløes Vej 3 DK-2200 Copenhagen N Denmark
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/26/3195234/0/en/IO-Biotech-Announces-Participation-in-Upcoming-December-Investor-Conferences.html

GLOBENEWSWIRE
26 Nov 2025

https://www.globenewswire.com/news-release/2025/11/14/3188282/0/en/IO-Biotech-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Business-Highlights.html

GLOBENEWSWIRE
14 Nov 2025

https://www.globenewswire.com/news-release/2025/11/12/3186252/0/en/IO-Biotech-Announces-Participation-in-Upcoming-Investor-Conferences.html

GLOBENEWSWIRE
12 Nov 2025

https://www.globenewswire.com/news-release/2025/11/07/3183674/0/en/IO-Biotech-Presents-Pre-Clinical-Data-Highlighting-the-Potential-of-Additional-Therapeutic-Cancer-Vaccine-Candidates-at-the-2025-Annual-Meeting-of-the-Society-for-Immunotherapy-of-.html

GLOBENEWSWIRE
07 Nov 2025

https://www.globenewswire.com/news-release/2025/10/20/3169094/0/en/IO-Biotech-Presents-Phase-3-Results-for-Cylembio-plus-KEYTRUDA-pembrolizumab-in-First-line-Advanced-Melanoma-at-ESMO-2025.html

GLOBENEWSWIRE
20 Oct 2025

https://www.fiercebiotech.com/biotech/io-lays-50-employees-after-fda-derails-cancer-vaccine-approval-plan

FIERCE BIOTECH
30 Sep 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty